137 related articles for article (PubMed ID: 12826887)
1. Hepatocyte antigen as a marker of intestinal metaplasia.
Chu PG; Jiang Z; Weiss LM
Am J Surg Pathol; 2003 Jul; 27(7):952-9. PubMed ID: 12826887
[TBL] [Abstract][Full Text] [Related]
2. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
3. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
4. Expression of sulfated carbohydrate chain and core peptides of mucin detected by monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma.
Endo T; Tamaki K; Arimura Y; Itoh F; Hinoda Y; Hareyama M; Irimura T; Fujita M; Imai K
J Gastroenterol; 1998 Dec; 33(6):811-5. PubMed ID: 9853552
[TBL] [Abstract][Full Text] [Related]
5. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma.
Ormsby AH; Goldblum JR; Rice TW; Richter JE; Gramlich TL
Histopathology; 2001 Apr; 38(4):307-11. PubMed ID: 11318895
[TBL] [Abstract][Full Text] [Related]
6. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.
Burjonrappa SC; Reddimasu S; Nawaz Z; Gao X; Sharma P; Loggie B
Indian J Cancer; 2007; 44(1):1-5. PubMed ID: 17401217
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus.
Gulmann C; Shaqaqi OA; Grace A; Leader M; Patchett S; Butler D; Kay E
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):142-7. PubMed ID: 15354740
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic differences between esophageal and gastric intestinal metaplasia.
Piazuelo MB; Haque S; Delgado A; Du JX; Rodriguez F; Correa P
Mod Pathol; 2004 Jan; 17(1):62-74. PubMed ID: 14631367
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
Ormsby AH; Goldblum JR; Rice TW; Richter JE; Falk GW; Vaezi MF; Gramlich TL
Hum Pathol; 1999 Mar; 30(3):288-94. PubMed ID: 10088547
[TBL] [Abstract][Full Text] [Related]
10. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry.
Sarbia M; Donner A; Franke C; Gabbert HE
Hum Pathol; 2004 Mar; 35(3):371-6. PubMed ID: 15017595
[TBL] [Abstract][Full Text] [Related]
11. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.
Flucke U; Steinborn E; Dries V; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP; Baldus SE
Histopathology; 2003 Aug; 43(2):127-34. PubMed ID: 12877727
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
[TBL] [Abstract][Full Text] [Related]
13. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.
Shi XY; Bhagwandeen B; Leong AS
Am J Clin Pathol; 2008 Apr; 129(4):571-7. PubMed ID: 18343784
[TBL] [Abstract][Full Text] [Related]
14. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
16. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
[TBL] [Abstract][Full Text] [Related]
17. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte antigen expression in subtypes of intestinal metaplasia of the stomach.
Ocak GA; Yildirim G; Elpek GO
West Indian Med J; 2012 Oct; 61(7):659-64. PubMed ID: 23620961
[TBL] [Abstract][Full Text] [Related]
20. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea?
Yim HJ; Lee SW; Choung RS; Kim YS; Kim JY; Lee HS; Song CW; Choi JH; Bak YT; Ryu HS; Hyun JH; Kim DS; Kim CH
Eur J Gastroenterol Hepatol; 2005 Jun; 17(6):611-6. PubMed ID: 15879722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]